Stany Zjednoczone - angielski - NLM (National Library of Medicine)

ranbaxy pharmaceuticals inc. - benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - benazepril hydrochloride 5 mg - benazepril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension (see dosage and administration). benazepril hydrochloride and hydrochlorothiazide tablets are contraindicated in patients who are anuric. benazepril hydrochloride and hydrochlorothiazide tablets are also contraindicated in patients who are hypersensitive to benazepril, to any other ace inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. hypersensitivity reactions are more likely to occur in patients with a history of allergy or bronchial asthma. benazepril hydrochloride and hydrochlorothiazide tablets are also contraindicated in patients with a history of angioedema with or without previous ace inhibitor treatment. do not co-administer aliskiren with angiotensin receptor blockers, ace inhibitors, including benazepril hydrochloride and hydrochlorothiazide tablets in patients with diabetes.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

golden state medical supply, inc. - benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - benazepril hydrochloride 5 mg - benazepril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension (see dosage and administration ). benazepril hydrochloride and hydrochlorothiazide tablets are contraindicated in patients who are anuric. benazepril hydrochloride and hydrochlorothiazide tablets are also contraindicated in patients who are hypersensitive to benazepril, to any other ace inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. hypersensitivity reactions are more likely to occur in patients with a history of allergy or bronchial asthma. benazepril hydrochloride and hydrochlorothiazide tablets are also contraindicated in patients with a history of angioedema with or without previous ace inhibitor treatment. benazepril hydrochloride and hydrochlorothiazide tablets are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer benazepri

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

sandoz inc - benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - benazepril hydrochloride 5 mg - benazepril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension (see dosage and administration). benazepril hydrochloride and hydrochlorothiazide is contraindicated in patients who are anuric. benazepril hydrochloride and hydrochlorothiazide is also contraindicated in patients who are hypersensitive to benazepril, to any other ace inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. hypersensitivity reactions are more likely to occur in patients with a history of allergy or bronchial asthma. benazepril hydrochloride and hydrochlorothiazide is also contraindicated in patients with a history of angioedema with or without previous ace inhibitor treatment. benazepril hydrochloride and hydrochlorothiazide is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer benazepril hydrochloride and hydrochlorothiazide within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see warnings and precautions ). do not coadminister aliskiren with angiotensin receptor blockers, ace inhibitors, including benazepril hydrochloride and hydrochlorothiazide in patients with diabetes.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

upsher-smith laboratories, llc - benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - benazepril hydrochloride 10 mg - benazepril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension (see dosage and administration). benazepril hydrochloride and hydrochlorothiazide is contraindicated in patients who are anuric. benazepril hydrochloride and hydrochlorothiazide is also contraindicated in patients who are hypersensitive to benazepril, to any other ace inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. hypersensitivity reactions are more likely to occur in patients with a history of allergy or bronchial asthma. benazepril hydrochloride and hydrochlorothiazide is also contraindicated in patients with a history of angioedema with or without previous ace inhibitor treatment. benazepril hydrochloride and hydrochlorothiazide is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer benazepril hydrochloride and hydrochlorothiazide within 36 hours o

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

rebel distributors corp - fexofenadine hydrochloride (unii: 2s068b75zu) (fexofenadine - unii:e6582loh6v), pseudoephedrine hydrochloride (unii: 6v9v2ryj8n) (pseudoephedrine - unii:7cuc9ddi9f) - fexofenadine hydrochloride 60 mg - fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see clinical pharmacology). fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets are contraindicated in patients with known hypersensitivity to any of its ingredients. due to its pseudoephedrine component, fexofenadine hydrochloride and pseudoephedrine hydrochloride extended-release tablets are contraindicated in patients with narrow-angle glaucoma or urinary retentio

Australia - angielski - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - ephedrine hydrochloride, quantity: 30 mg - injection, solution - excipient ingredients: water for injections - ephedrine hydrochloride injection is indicated in the treatment of hypotension secondary to spinal anaesthesia.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

physicians total care, inc. - colestipol hydrochloride (unii: x7d10k905g) (colestipol - unii:k50n755924) - colestipol hydrochloride 1 g - since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. micronized colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and ldl-c in patients with primary hypercholesterolemia (elevated ldl-c) who do not respond adequately to diet. generally, micronized colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy (see ncep guidelines). a minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. shorter pe

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

proficient rx lp - diethylpropion hydrochloride (unii: 19v2pl39ng) (diethylpropion - unii:q94yyu22b8) - diethylpropion hydrochloride 75 mg - diethylpropion hydrochloride extended release tablets, 75 mg are indicated in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (bmi) of 30 kg/m2 or higher and who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. below is a chart of bmi based on various heights and weights. bmi is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. metric conversions are as follows: pounds divided by 2.2 = kg; inches x 0.0254 = meters. body mass index (bmi), kg/m2 weight (pounds) height (feet, inches)   5’0” 5’3” 5’6” 5’9” 6’0” 6’3” 140 27 25 23 21 19 18 150 29 27 24 22 20 19 160 31 28 26 24 22 20 170 33 30 28 25 23 21 180 35 32 29 27 25 23 190 37 34 31 28 26 24 200 39 36 32 30 27 25 210 41 37 34 31 29 26 220 43 39 36 33 30 28 230 45 41 37 34 31 29 240 47 43 39 36 33 30 250 49 44 40 37 34 31

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - diethylpropion hydrochloride (unii: 19v2pl39ng) (diethylpropion - unii:q94yyu22b8) - diethylpropion hydrochloride 75 mg - diethylpropion hydrochloride extended release tablets, 75 mg are indicated in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (bmi) of 30 kg/m 2 or higher and who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. below is a chart of bmi based on various heights and weights. bmi is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. metric conversions are as follows: pounds divided by 2.2 = kg; inches x 0.0254 = meters. body mass index (bmi), kg/m 2 weight (pounds) height (feet, inches) 5’0” 5’3” 5’6” 5’9” 6’0” 6’3” 140 27 25 23 21 19 18 150 29 27 24 22 20 19 160 31 28 26 24 22 20 170 33 30 28 25 23 21 180 35 32 29 27 25 23 190 37 34 31 28 26 24 200 39 36 32 30 27 25 210 41 37 34 31 29 26 220 43 39 36 33 30 28 230 45 41 37 34 31 29 240 47 43 39 36 33

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - diethylpropion hydrochloride (unii: 19v2pl39ng) (diethylpropion - unii:q94yyu22b8) - diethylpropion hydrochloride 75 mg - diethylpropion hydrochloride extended release tablets, 75 mg are indicated in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (bmi) of 30 kg/m2 or higher and who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. below is a chart of bmi based on various heights and weights. bmi is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. metric conversions are as follows: pounds divided by 2.2 = kg; inches x 0.0254 = meters. body mass index (bmi), kg/m2 weight (pounds) height (feet, inches)   5’0” 5’3” 5’6” 5’9” 6’0” 6’3” 140 27 25 23 21 19 18 150 29 27 24 22 20 19 160 31 28 26 24 22 20 170 33 30 28 25 23 21 180 35 32 29 27 25 23 190 37 34 31 28 26 24 200 39 36 32 30 27 25 210 41 37 34 31 29 26 220 43 39 36 33 30 28 230 45 41 37 34 31 29 240 47 43 39 36 33 30 250 49 44 40 37 34 31